Prognostic Impact of IMDC Category Shift From Baseline to Nivolumab Initiation in Metastatic Renal Cell Carcinoma: A Sub-Analysis of the MEET-URO 15 Study.

Prognostic Impact of IMDC Category Shift From Baseline to Nivolumab Initiation in Metastatic Renal Cell Carcinoma: A Sub-Analysis of the MEET-URO 15 Study.

Autore

Brigida Anna Maiorano

Patologia

Rene

Rivista

Clinical Genitourinary Cancer

Anno

2024

DOI

https://doi.org/10.1016/j.clgc.2024.102267

Studio di riferimento

Meet-URO 15